<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01167010</url>
  </required_header>
  <id_info>
    <org_study_id>EF111</org_study_id>
    <nct_id>NCT01167010</nct_id>
  </id_info>
  <brief_title>A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma</brief_title>
  <acronym>UNIK</acronym>
  <official_title>A Phase III, Randomized, Non-inferiority, Open-label, Comparative Study Between Foraseq® Inhalation Capsules, Eurofarma's Single Formoterol / Budesonide Inhalation Capsule and Single Alenia® Inhalation Capsule in Asthmatic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurofarma Laboratorios S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurofarma Laboratorios S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective will be to compare the Eurofarma and Alenia formulations regarding
      their impact on the pulmonary function of mild to moderate persistent asthma patients and the
      secondary objective will be to compare the three study formulations regarding the clinical
      control of the symptoms and the patients' compliance to the treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>forced expiratory volume in 1 second (FEV1) at the final visit (FV)</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>asthma control score in the Asthma Control Questionnaire-7 (ACQ-7)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">552</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Formoterol/Budesonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>formoterol and budesonide will be administered at the 12/400 µg dosage, twice a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Foraseq</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alenia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol/Budesonide</intervention_name>
    <description>formoterol and budesonide will be administered at the 12/400 µg dosage, twice a da for 12 weeks.</description>
    <arm_group_label>Formoterol/Budesonide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foraseq</intervention_name>
    <description>foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.</description>
    <arm_group_label>Foraseq</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alenia</intervention_name>
    <description>Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.</description>
    <arm_group_label>Alenia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign the ICF;

          -  ≥ 12 years old;

          -  Have a diagnosis of mild to moderate persistent asthma diagnosis, as per the GINA
             classification (www.ginasthma.com),18 with symptoms for at least 6 months and
             clinically stable for at least 1 month with the ACQ-7 test &lt;3,0;

          -  Current use of inhaled corticosteroid (equivalent to 1000 µg of beclomethasone
             dipropionate) whether associated or not with long-term β2 adrenergics and relief
             medication (salbutamol or equivalent);

          -  Initial FEV1 of at least 50% of the normal value expected;

          -  Serum cortisol evaluation within the normal limits

        Exclusion Criteria:

          -  Use of oral or parenteral corticosteroid within the last 3 months before the study;

          -  Hospitalization needed due to asthma within the last 3 months before the study;

          -  Active smokers, defined as the consumption of cigarettes, pipes, cigars, or any other
             form of smoking in any amount within the last 3 months;

          -  Presence of serious co-morbidities, such as cardiovascular, renal, liver,
             neurological, neoplastic, hematological, infectious, dermatologic, neurological, or
             psychiatric disease, or chronic respiratory disease other than asthma;

          -  Recent participation (&lt;6 months) or expected participation in other clinical trials
             involving drug products of any nature or in studies consisting of any form of
             intervention for the treatment of asthma;

          -  Intolerance or allergy to any component of the drugs evaluated in the study;

          -  Pregnant or lactating women;

          -  Chronic use of routine β-blockers orally or intravenously, including ophthalmic
             solutions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centro de Referencia em Enfermidades Respiratoria e Alergica</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas UFPR</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Alergia Martti Antila</name>
      <address>
        <city>Sorocaba</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMA Brasil - Instituto de Pesquisa Clínica e Medicina Avançada</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stelmach Pesquisa Clinica</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2010</study_first_submitted>
  <study_first_submitted_qc>July 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2010</study_first_posted>
  <last_update_submitted>May 4, 2012</last_update_submitted>
  <last_update_submitted_qc>May 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2012</last_update_posted>
  <responsible_party>
    <name_title>Ana Lúcia Koff Milan</name_title>
    <organization>Eurofarma Laboratorios Ltda</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

